%0 Journal Article %A Kanwar, Navjot %A Sinha, Vivek Ranjan %D 2019 %I Begell House %K controlled release, PLGA, NMP, syringeability, Regel technology %N 2 %P 93-136 %R 10.1615/CritRevTherDrugCarrierSyst.2018025013 %T In Situ Forming Depot as Sustained-Release Drug Delivery Systems %U https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,389e9bee07f1e347,67c567105161e7ef.html %V 36 %X In situ forming systems can serve as promising alternative to existing long acting injectables like disperse systems and microspheres, owing to their biocompatibility, stability, ease of administration and scale up. Microspheres based on long-acting parenteral systems pose challenges in scaling up and process changes with the drug and polymer selected. In situ gelling systems are having low viscosity which is very conducive during various manufacturing unit operations and passing the formulation through hypodermic needle with lower applied pressure. Different mechanisms such as physical or physiological stimuli and cross linking reactions are involved in the gelling of in situ forming systems at the site of injection. Drug release from in situ forming systems can be altered according to the need by using different polymers, lipids and fatty acids. In situ forming systems can be evaluated by sol-gel transition time, temperature and pH, rheology, gel strength, texture analysis, syringeability and injectability. The present paper is an overview of the various in situ gelling polymers and their application in the preparation of depot formulations. Numerous products based on in situ forming systems such as Eligard®, Atridox® are available in market. %8 2018-11-29